ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.34 +0.42%

+$0.04 today

Market cap
$2.96B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.62M

Average 7.07M

Income Statement

Follow revenue through to earnings.

Revenue

$510.17M

FY 2025 · Annual

+19.6% YoY

Operating Income

$191.44M

FY 2025 · Annual

+37.7% YoY

Net Income

$146.93M

FY 2025 · Annual

-25.7% YoY

Income Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Earnings Waterfall · TTM

NASDAQ:ADMA · Revenue to Net Income

Key Ratios

EPS$0.70
Gross Margin65.0%
Net Margin33.2%
P/E Ratio17.6
P/S Ratio22.8

Analysis

$512.3M of revenue converted into $169.0M of net income for the selected period. Gross margin is 65.0% and net margin is 33.2%, showing how much revenue survives after costs and taxes. EPS is $0.70, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
10-QQuarterly reportNov 4, 2026
8-KCurrent reportNov 4, 2026
SC 13GSC 13G filingAug 7, 2026

How much revenue does ADMA generate?

ADMA Biologics, Inc. (ADMA) reported $510.17M of revenue in fiscal 2025.

Is ADMA profitable?

ADMA Biologics, Inc. (ADMA) reported $146.93M of net income, with a net margin of 28.8%.